Belantamab (GSK2857914, CAS 2061894-48-0) is a monoclonal antibody that targets BCMA, a protein overexpressed on myeloma cells. It can be used to create the antibody-drug conjugate (ADC) Belantamab mafodotin. This ADC combines a humanized IgG1κ monoclonal antibody with the cytotoxic agent mcMMAF, allowing targeted delivery to BCMA-expressing myeloma cells and minimizing damage to healthy tissue.
Key Features:
- Target Specificity: Binds to BCMA on myeloma cells.
- Mechanism of Action: Delivers mcMMAF to myeloma cells, causing cell death.
- Molecular Characteristics: Humanized IgG1κ monoclonal antibody with mcMMAF.
Applications:
- Multiple Myeloma Treatment: Treats relapsed or refractory multiple myeloma after four prior therapies.
- Antibody-Drug Conjugates (ADCs): Used for targeted drug delivery.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
